Psilocybin May be the Key to Treating a Range of Health Issues, Including Obesity – Baystreet.ca

Psilocybin mushrooms may change the way we look at medicine and significantly help improve the health of millions of people around the world. That may be especially true when it comes to treating obesity, which has been recognized by the World Health Organization as a global epidemic, with at least 2.8 million people dying each year as a result.

At the moment, a number of studies show psychedelic treatments, such as with psilocybin mushrooms can assist with issues such as substance dependency, PTSD, depression, anxiety, obsessive compulsive disorder, and pain. Even Johns Hopkins Medicines Center for Psychedelic and Consciousness Research is focusing on psychedelics, including psilocybin for the treatment of eating disorders, depression, and PTSD. As the growth story unfolds, some of the companies to keep an eye on include The Yield Growth Corp.(CSE:BOSS)(OTC:BOSQF), Johnson & Johnson (NYSE:JNJ), Champignon Brands Inc. (OTC:SHRMF)(CSE:SHRM), Mind Medicine Inc. (OTC:MMEDF), and Revive Therapeutics Ltd. (CSE:RVV)(OTC:RVVTF).

The Yield Growth Corp.(CSE:BOSS)(OTCQB:BOSQF)BREAKING NEWS:The Yield Growth Corp. announced its majority owned subsidiary NeonMind has completed the design of a preclinical study to confirm that psilocybin (found in psychedelic mushrooms) is an effective treatment for weight loss and food craving. NeonMind engaged Translational Life Sciences Inc., a contract research organization, to design the study. The TLS team is composed of physicians and scientists who are recognized thought leaders in the fields of Neurology, Pharmacology, Diabetes, Addiction and Biochemistry and have significant experience in the clinical application of cannabinoid compounds.

The goal of the study is to use preclinical models to confirm that psilocybin is an effective treatment for weight loss and food craving. NeonMind will use models that have been widely adopted by the pharmaceutical industry to identify compounds with therapeutic efficacy. It plans to use results from this study as part of the requirements for a Health Canada clinical trial application to demonstrate potential efficacy and safety for novel compounds.

Obesity has been formally recognized by the World Health Organization as a global epidemic, with at least 2.8 million people dying each year as a result of being overweight or obese. According to the WHO, in 2016, more than 1.9 billion adults, 18 years and older, were overweight. Of these over 650 million were obese. Overweight and obesity is defined as abnormal or excessive fat accumulation that presents a risk to health.

According to the WHO, in its Global Strategy on Diet, Physical Activity and Health, a unique opportunity exists to formulate and implement an effective strategy for substantially reducing deaths and disease worldwide by improving diet and promoting physical activity. The global projected market for weight loss and weight management is estimated at US$245 billion, according to MarketsandMarkets.

NeonMind plans to complete the study in Canada in accordance with all Health Canada rules and regulations. Required permits and exemptions have not been yet applied for, but shall be obtained prior to the study taking place.

Other related developments from around the markets include:

Johnson & Johnson (NYSE:JNJ) will participate in Bernstein's 36thAnnual Strategic Decisions Virtual Conference on Wednesday, May 27th. Alex Gorsky, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time).

Champignon Brands Inc. (OTC:SHRMF)(CSE:SHRM) announced its placement in an editorial published byNetworkNewsWire. The expansion of the functional food and drinks sector has created a new opportunity. While cannabis and CBD have taken these consumables beyond the traditional active ingredients of alcohol and caffeine, this diversification of the market has opened up consumers to new possibilities. Among those possibilities is the use of natural ingredients found in mushrooms.

Mind Medicine Inc. (OTC:MMEDF) in collaboration with University Hospital Basels Liechti Laboratory, has discovered and filed a patent application in the United States (preserving all worldwide rights) for a neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session. This discovery, when further developed, may act as the off-switch to an LSD trip. MindMed is the leading psychedelic pharmaceutical company and the Liechti Laboratory is the leading research center focused on the pharmacology of psychedelic substances. This is the latest discovery based on surprising experimental results from work and collaboration conducted at the lab. The invention may help reduce the acute effects of a psychedelic drug and help shorten the hallucinogenic effects when required by a patient or medical professional. One of the many fears and stigmas associated with psychedelics are rare occurrences of bad trips. MindMed is seeking to equip therapists and other medical professionals with the resources and technology to better control the effects of dosing LSD in a clinical setting to improve the patient experience and patient outcomes. This advancement paves the way for greater therapeutic applications of LSD and shorter-acting psychedelic therapy treatments. MindMed believes this technology, when further developed, may one day be marketed as an added feature to shorten a therapy session and stop a session if the patient is not comfortable.

Revive Therapeutics Ltd. (CSE:RVV)(OTC:RVVTF) will investigate novel oral dosage forms of psilocybin, such as oral dissolvable thin films or tablets, based on the Companys wholly-owned patent-pending psilocybin formulations and its exclusive licensed drug delivery technology from the Wisconsin Alumni Research Foundation. We are expanding our psilocybin-based pharmaceutical portfolio with unique oral dosage and drug delivery forms that will target and have the potential to treat diseases and disorders currently not investigated with psychedelic compounds, said Michael Frank, Revives Chief Executive Officer. We are combining our robust intellectual property portfolio in both psychedelic formulations and our drug delivery technology which is unique within the industry, and leveraging our research partnership with the University of Wisconsin-Madison to establish a specialty portfolio of psilocybin-based pharmaceuticals that we can advance to clinical trials and partnerships with other life sciences companies. Through initial evaluations with the Companys research team, it has been found there are several unique parallels between the Companys intellectual property portfolio of psilocybin-based formulations and delivery mechanism and the drug delivery technology, which is comprised of tannin-chitosan composites that have been studied with cannabidiol in the past. Revive intends to research both delivery mechanisms in parallel as each provides its own unique qualities such as the potential of rapid onset of action and time-release compositions. The future of psilocybin as a medication will come in many forms. The Company believes that the most optimal delivery method to pursue and unlock the potential of psilocybin to treat a broad spectrum of diseases and disorders will be in the form of both an oral dissolvable tablet and an oral thin film strip, commonly recognized as a Breath Strip. The Company is preparing its formulation development plans intending to pursue clinical studies for indications currently not being evaluated with psilocybin. We believe the combination of psilocybin and our tannin-chitosan delivery platform gives us a unique advantage.

Legal Disclaimer/ Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with http://www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with http://www.MarijuanaStox.com, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of http://www.MarijuanaStox.com) and The Yield Growth Corp., Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here forfull disclaimer.

Contact Information: 2818047972ty@MarijuanaStox.com

More here:

Psilocybin May be the Key to Treating a Range of Health Issues, Including Obesity - Baystreet.ca